2006 Annual Meeting | Therapeutic Poisoning: Immunosuppressive Therapy for Non-neoplastic Neurological Disease

Date Saturday 04/08/06

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Michael Glantz, MD, FAAN

Topic(s)

Learning Objectives Upon Completion:
Participants should be able to describe the currently available classes of immunosuppressive and myelosuppressive agents, their neurological and non-neurological toxicities, and the practical aspects of their administration; explain the rationale and optimum strategies for the use of these agents in a wide spectrum of primary and secondary nervous system disorders; establish a safe and efficient office-based program for the use of immunosuppressive and myelosuppressive therapies in patients with nervous system diseases; develop algorithms for treatment and monitoring and apply standardized metrics for assessing outcome; and discuss the evolving role of immune system ablation in the treatment of immune-mediated nervous system disorders such as multiple sclerosis, Behçet's disease, and Sneddon's syndrome.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
09:00 AM - 09:35 AM		Immunosuppressive Therapy in Demyelinating Disease: How I Do It Patricia K. Coyle, MD, FAAN
09:35 AM - 10:10 AM		Immunosuppressive Therapy in Neuromuscular Disease: How I Do It Marinos C. Dalakas, MD, FAAN
10:10 AM - 10:45 AM		Rebooting the Immune System: To Transplant or Replant Douglas A. Kerr, MD, PhD
10:45 AM - 11:00 AM		Break
11:00 AM - 11:30 AM		Managing the Toxicities of Immunusuppression in the Office Setting I Michael Glantz, MD, FAAN
11:30 AM - 12:00 PM		Managing the Toxicities of Immunosuppression in the Office Setting II Camilo E. Fadul, MD, FAAN
12:00 PM - 12:20 PM		Case Presentations: Demyelinating Disease Patricia K. Coyle, MD, FAAN
12:20 PM - 12:40 PM		Case Presentations: Neuromuscular Disease Marinos C. Dalakas, MD, FAAN

Faculty Disclosures
Michael Glantz, MD, FAAN	No disclosure on file
Patricia K. Coyle, MD, FAAN	Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant. Dr. Coyle has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Coyle has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi Genzyme. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Company. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GlaxoSmithKline. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon Therapeutics. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Coyle has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Coyle has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mylan. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viatris. Dr. Coyle has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Coyle has received research support from CorEvitas LLC. The institution of Dr. Coyle has received research support from Genentech/Roche. The institution of Dr. Coyle has received research support from NINDS. The institution of Dr. Coyle has received research support from Sanofi Genzyme. The institution of Dr. Coyle has received research support from Celgene.
Marinos C. Dalakas, MD, FAAN	Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx,. Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.
Daniel B. Drachman, MD, FAAN	No disclosure on file
Camilo E. Fadul, MD, FAAN	No disclosure on file
Douglas A. Kerr, MD, PhD	Dr. Kerr has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Kerr has received personal compensation for serving as an employee of Generation Bio. Dr. Kerr has received personal compensation for serving as an employee of Atlas Venture. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for BlueRock Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for AAVantgarde Therrapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Trace Neuroscience. Dr. Kerr has stock in Dyne Therapeutics. Dr. Kerr has stock in Generation Bio.

��ɫ��

��ɫ��